Official Journal of Research Center for Gastroenterology and Liver Diseases
CrossRef
Works that cite this article, indexed by Crossref.
New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)
Canadian Journal of Physiology and Pharmacology 94(6) (2016)
Payam Peymani; Behzad Yeganeh; Siamak Sabour; Bita Geramizadeh; Mohammad Reza Fattahi; Hossein Keyvani; Negar Azarpira; Kevin M. Coombs; Saied Ghavami; Kamran B. Lankarani
Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
Hepatitis Monthly 16(4) (2016)
Khashayar Hesamizadeh; Heidar Sharafi; Mohammad Saeid Rezaee-Zavareh; Bita Behnava; Seyed Moayed Alavian
A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran
Cost Effectiveness and Resource Allocation 23(1) (2025)
Mojtaba Jafari; Parisa Mehdizadeh; Khosro Keshavarz; Ehsan Teymourzadeh; Mohammad Ali Abyazi; Seyed Moayed Alavian; Alijanpour Pouria
Occult HCV Infection: The Current State of Knowledge
Iranian Red Crescent Medical Journal 17(11) (2015)
Mohammad Saeid Rezaee-Zavareh; Reza Hadi; Hamidreza Karimi-Sari; Mohammad Hossein Khosravi; Reza Ajudani; Fardin Dolatimehr; Mahdi Ramezani-Binabaj; Seyyed Mohammad Miri; Seyed Moayed Alavian
A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
Iranian Red Crescent Medical Journal 18(11) (2016)
Seyed Moayed Alavian; Shekoufeh Nikfar; Abbas Kebriaeezadeh; Farhad Lotfi; Ehsan Sanati; Mohsen Rezaei Hemami; Khosro Keshavarz
Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review
Cost Effectiveness and Resource Allocation 24(1) (2025)
Mojtaba Jafari; Parisa Mehdizadeh; Ehsan Teymourzadeh; Mahmood Salesi; Khosro Keshavarz; Mohammad Ali Abyazi; Mohammad Heiat; Seyed Moayed Alavian
Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C
Hepatitis Monthly 21(8) (2021)
Zahra Goudarzi; Abdollah Poursamad; Iman Karimzadeh; Nahid Jallaly; Khosro Keshavarz; Seyed Moayed Alavian
Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study
BMJ Open 15(9) (2025)
Mojtaba Jafari; Parisa Mehdizadeh; Khosro Keshavarz; Ehsan Teymourzadeh; Mohammad Ali Abyazi; Parsa Gholamreza Shirazi